Stay updated with breaking news from Results Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...
Share: Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard ® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, today announced that it has reached agreement with the US Food and...
Xenikos B.V.: Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021 Positive Results Expected to Support Both FDA and EMA Regulatory Submissions NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) -- Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease ...